|
PD-L1 t-haNK Clinical Trials
2 actively recruiting trials across 2 locations
Also known as: NK-92
El Segundo, California1 trial
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Chan Soon-Shiong Institute for Medicine (CSSIFM)
Phase 2
Boston, Massachusetts1 trial
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Brigham and Women's Hospital
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.